Purinergic signaling in Parkinson’s disease (2023)
- Authors:
- USP affiliated authors: ULRICH, ALEXANDER HENNING - IQ ; BRITTO, LUIZ ROBERTO GIORGETTI DE - ICB ; SILVA, JEAN BEZERRA - IQ ; FERREIRA, ANA FLAVIA FERNANDES - ICB ; GLASER, TALITA - IQ
- Unidades: IQ; ICB
- Assunto: DOENÇA DE PARKINSON
- Language: Inglês
- Imprenta:
- Source:
- Título: Purinergic signaling in neurodevelopment, neuroinflammation and neurodegeneration
- Volume/Número/Paginação/Ano: 376 p
-
ABNT
SILVA, Jean Bezerra et al. Purinergic signaling in Parkinson’s disease. Purinergic signaling in neurodevelopment, neuroinflammation and neurodegeneration. Tradução . Cham: Springer, 2023. . . Acesso em: 27 dez. 2025. -
APA
Silva, J. B., Ferreira, A. F. F., Glaser, T., Ulrich, H., & Britto, L. R. G. de. (2023). Purinergic signaling in Parkinson’s disease. In Purinergic signaling in neurodevelopment, neuroinflammation and neurodegeneration. Cham: Springer. -
NLM
Silva JB, Ferreira AFF, Glaser T, Ulrich H, Britto LRG de. Purinergic signaling in Parkinson’s disease. In: Purinergic signaling in neurodevelopment, neuroinflammation and neurodegeneration. Cham: Springer; 2023. [citado 2025 dez. 27 ] -
Vancouver
Silva JB, Ferreira AFF, Glaser T, Ulrich H, Britto LRG de. Purinergic signaling in Parkinson’s disease. In: Purinergic signaling in neurodevelopment, neuroinflammation and neurodegeneration. Cham: Springer; 2023. [citado 2025 dez. 27 ] - Deletion of the transient receptor potential melastatin 2 gene mitigates the 6-hyydroxydopamine-induced Parkinson’s Disease–Like Pathology
- Deletion of the transient receptor potential Melastatin 2 gene mitigates the 6-hydroxydopamine-induced parkinson’s disease–like pathology
- Neurodegeneration and glial morphological changes are both prevented by TRPM2 inhibition during the progression of a Parkinson's disease mouse model
- The role of interleukin-17 in neurological disorders
- Inhibition of neuroinflammation by GIBH-130 (AD-16) reduces neurodegeneration, motor deficits, and proinflammatory cytokines in a hemiparkinsonian model
- The transient receptor potential melastatin 2: a new therapeutical target for Parkinson’s disease?
- Purinergic receptors in neurogenic processes
- Purinergic signaling: an overview
- Huntingtin protein maintains balanced energetics in mouse cardiomyocytes
- Purinergic signaling in brain physiology
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
